| Filed On | Filing |
|---|---|
| 11 Aug 2021 |
8-K/A: Departure/Election of Directors or Officers; Compensation
On July 8, 2021, the Company filed the Original Filing disclosing that the Company’s Board of Directors (the “Board”) had appointed Dr. Robert Michael Poole as a director of the Company effective July 9, 2021. At the time of filing of th... |
| 17 Jun 2019 |
8-K/A: Entry into a Material Definitive Agreement
[***] = Certain confidential information contained in this document, marked by brackets, is omitted because it is not material and would be competitively harmful if publicly disclosed. |
| 28 Mar 2019 |
8-K/A: Departure/Election of Directors or Officers; Compensation; Other Events
NEW YORK – March 28, 2019 - Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological disorders, today announced changes to its senior m... |
Loading...